Dexibuprofen
| Evidence Level: L5 | Predicted Indications: 8 |
Table of Contents
Dexibuprofen: NSAID (COX inhibitor) → brachydactyly-syndactyly syndrome
One-Sentence Summary
Dexibuprofen is a nonsteroidal anti-inflammatory drug (NSAID), the S-enantiomer of ibuprofen, which inhibits cyclooxygenase (COX). The TxGNN model predicts it may be relevant to brachydactyly-syndactyly syndrome, but this is a computational prediction only: no clinical trials and no publications were found to support it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | brachydactyly-syndactyly syndrome |
| TxGNN Prediction Score | 0.9987 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (5 of 5) – CDSCO approval status is not included in this data |
| Number of Listed Products | 5 (valid: 5) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available. Based on known pharmacology, dexibuprofen is the active S-enantiomer of ibuprofen and works by inhibiting COX enzymes, which reduces prostaglandin-mediated inflammation and pain.
Brachydactyly-syndactyly syndrome is a congenital malformation of the digits. Its cause is developmental and genetic, not inflammatory. There is no recognized mechanism by which COX inhibition would change the course of a congenital skeletal malformation. The high score appears to reflect model-based proximity to musculoskeletal terms rather than a demonstrated biological link. This prediction should be treated as a hypothesis with a weak mechanistic basis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 63789 | Debura 300 mg/500 mg Tablet | Strip of 10 tablets | Not recorded |
| 155424 | Nuprin 200 Tablet | Strip of 10 tablets | Not recorded |
| 153219 | Nuprin 300mg Tablet | Strip of 10 tablets | Not recorded |
| 109579 | Ibusoft 400mg Tablet | Strip of 10 tablets | Not recorded |
| 153180 | Nuprin Plus Tablet | Strip of 10 tablets | Not recorded |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score. There are no clinical trials or publications for this disease, and COX inhibition has no plausible effect on the underlying congenital malformation.
To proceed, the following is needed:
- Any direct preclinical or clinical evidence linking dexibuprofen to this condition
- Detailed mechanism of action data and a plausible biological rationale
- Package insert warnings and contraindications for safety screening
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.